Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that causes severe and irreversible vision loss. The disease can therefore have a significant impact on the life of patients' and their families. The aim of this study was to evaluate the socio-economic burden of nAMD in Spain. METHODS: The annual cost per patient with nAMD was estimated for the first, second, and third year (or beyond) of treatment since diagnosis. Several cost categories were considered including direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labor productivity losses (LPL), and intangible costs (IC) related to loss of quality of life. The average annual cost per patient was estimated by assigning a unit price or financial proxy to the resources consumed per patient. Reference year of costs was 2021. RESULTS: The mean annual cost of nAMD was estimated at €17,265, €15,403, and €14,465 per patient in the first, second, and third year of treatment after diagnosis. There was an additional one-off cost of €744 associated with the diagnosis of nAMD. DHC accounted for most of the total annual cost per patient independent of the year of treatment since diagnosis (48% in year 1; 42% in year 2; 39% in year 3). Similarly, DNHC had an important contribution to the total costs (32% in year 1; 35% in year 2; 37% in year 3), followed by IC (20% in year 1; 23% in year 2; 24% in year 3), while the contribution of patients' LPL was minimal. CONCLUSION: This study estimated a high economic burden associated with nAMD for patients and their families, the healthcare system, and society at large. There is a need to improve the management of these patients to reduce the impact of nAMD disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Annual productivity loss in patients ranged from $23 to $1,006 [34, 39].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The loss of productivity, pertaining to the reduction in labour force and wages, among nAMD patients was estimated in two studies [34, 39], and carers in one [37] (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, intangible costs related to the impact of the disease on the patient’s quality of life and daily activities were estimated annually at the patient level in one model-based study ($6,185) [34].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In terms of informal care costs, they were estimated in two studies [34, 39], ranging from $2,508 to $6,634 per patient per annum.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 2×
“Moreover, nAMD is the most common cause of irreversible vision loss in people over 60 in developed countries [3].”
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639 · cited 1×
“Prompt diagnosis and treatment of nAMD has the potential to maintain vision as there are pharmacological therapies that significantly improve the prognosis of these patients [16].”
Li, J. Q., Welchowski, T., Schmid, M., Mauschitz, M. M., Holz, F. G., & Finger, R. P. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-314422 · Cited by 381 · cited 1×
“In Europe, 1.4% of the population aged 60 years or over have nAMD [13].”
InfluentialEconomic Note: Cost of illness studies
Byford, S. (2000) · BMJ · doi:10.1136/bmj.320.7245.1335 · Cited by 318 · cited 1×
“Given the prevalence approach used in the present study, the cost of diagnosis was not included in the TC [26].”
Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias
López Bastida, J., Oliva, J., Antoñanzas, F., García-Altés, A., Gisbert, R., Mar, J., & Puig-Junoy, J. (2010) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2009.07.011 · Cited by 311 · cited 1×
“Moreover, to estimate the impact on quality of life, quality-adjusted life years (QALYs) were used, where one QALY is equivalent to 1 year in perfect health [20].”
Quality of life in age-related macular degeneration: a review of the literature
Mitchell, J., & Bradley, C. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-97 · Cited by 304
Taylor, D. J., Hobby, A. E., Binns, A. M., & Crabb, D. P. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011504 · Cited by 288 · cited 1×
“…vision may impair the patient’s activities of daily living (e.g., self-care, shopping, driving, etc.), leisure activities (e.g., watching television, reading, etc.), as well as work productivity for both patients and caregivers [9, 10], causing an important burden for families and society at large.”
Updates on the Epidemiology of Age-Related Macular Degeneration
(2017) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2017251 · Cited by 266 · cited 1×
“The number of people affected by nAMD will continue to increase in the coming years as a consequence of the exponential aging of the population [3], just as the number of people affected by blindness due to nAMD will increase [14].”
The burden of neovascular age-related macular degeneration: a patient’s perspective
Spooner, K., Mhlanga, C., Hong, T., Broadhead, G., & Chang, A. (2018) · Clinical Ophthalmology · doi:10.2147/opth.s185052 · Cited by 121 · cited 1×
“…vision may impair the patient’s activities of daily living (e.g., self-care, shopping, driving, etc.), leisure activities (e.g., watching television, reading, etc.), as well as work productivity for both patients and caregivers [9, 10], causing an important burden for families and society at large.”
Lafuma, A., ́zin, A. P. B., Lopatriello, S., Hieke, K., Hutchinson, J., Jeanbat-Mimaud, V., & Berdeaux, G. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624020-00007 · Cited by 85 · cited 1×
“The progression of nAMD leads to vision loss, which in turn carries a significant economic and social burden for the patients, their families, and society as a whole [15].”
Giocanti‐Auregan, A., García‐Layana, A., Pető, T., Gentile, B., Chi, G. C., Mirt, M., Kosmas, C. E., Lambert, J., Lanar, S., Lewis, H. B., et al. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s347713 · Cited by 64
Neovascular AMD: an overlooked risk factor for injurious falls
Szabo, S. M., Janssen, P. A., Khan, K. M., Lord, S. R., & Potter, M. J. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1025-8 · Cited by 45 · cited 2×
“Accordingly, nAMD has been associated with a greater risk of injurious falls [4], impaired activities of daily living [5], and worse psychological well-being than non-neovascular AMD [5].”
Ruiz-Moreno, J. M., Arias, L., Abraldes, M. J., Montero, J., Udaondo, P., & The RAMDEBURS study group (2021) · International Ophthalmology · doi:10.1007/s10792-021-01906-x · Cited by 41 · cited 3×
“Our estimates of DHC are higher than those reported in Ruíz-Moreno et al. (2021), especially in the first year of treatment, which can be expected considering that more intense treatment and closer monitoring is necessary at such point in time and the advanced disease stage of nAMD.”
InfluentialSelf-citationHernández-Pastor, L. J., Ortega, A., García‐Layana, A., & Giráldez, J. (2009) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1156-9 · Cited by 39 · cited 3×
“There are a series of adverse events (AEs) and complications associated with intravit-real injections in patients with nAMD, including retinal detachment, corneal damage, and endophthalmitis [7].”
InfluentialViggiano, P., Grassi, M. O., Pignataro, M. G., Boscia, G., Borrelli, E., Molfetta, T., Evangelista, F., Alessio, G., & Boscia, F. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.9.18 · Cited by 39
Burden of illness of bilateral neovascular age-related macular degeneration in Spain
María Ruiz-Moreno, J., María Coco, R., García-Arumí, J., Xu, X., & Zlateva, G. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802214300 · Cited by 36
Giocanti‐Auregan, A., García-Layana, A., Pető, T., Gentile, B., Chi, G. C., Mirt, M., Kosmas, C. E., Lambert, J., Lanar, S., Lewis, H. B., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 34
Marín, B. P., Paniagua, N. M. G., Gómez‐Baldó, L., & Gallego‐Pinazo, R. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211001716 · Cited by 31 · cited 3×
“Previous studies have shown that nAMD generates large DHC [33].”
InfluentialRuiz‐Moreno, J. M., Arias, L., Armadá-Maresca, F., Boixadera, A., García‐Layana, A., Gómez-Ulla-de-Irazazábal, F., Carilla, J. M., Piñero-Bustamante, A., & Suarez‐Figueroa, M. (2009) · Archivos de la Sociedad Española de Oftalmología · doi:10.4321/s0365-66912009000700004 · Cited by 28
Self-citationFernández‐Vigo, J. I., Burgos‐Blasco, B., Calvo-González, C., Escobar-Moreno, M. J., Shi, H., Jiménez-Santos, M., Valverde-Megías, A., Reche-Frutos, J., López-Guajardo, L., & Donate-López, J. (2021) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2020.11.008 · Cited by 12
Fernández-Vigo, J. I., Burgos-Blasco, B., Calvo-González, C., Escobar-Moreno, M. J., Shi, H., Jiménez-Santos, M., Valverde-Megías, A., Reche-Frutos, J., López-Guajardo, L., & Donate-López, J. (2021) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2020.11.010 · Cited by 8 · cited 2×
“Furthermore, these patients present depression and anxiety disorders [11] with an incidence of depression twice as high as that for people without nAMD [12].”
Influential
Research works printed but not linked: 1
- NICE. Age-related macular degeneration: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018. PMID: 29400919.
Cited by
Zhou, Y., & Xue, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1507860 · Cited by 6
Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration
Zhou, B., Mokhashi, N., & Skondra, D. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2635492 · Cited by 2
“In the U.S., there is a high economic burden associated with long-term treatment [9], and late-stage AMD can be associated with up to $49.4 billion in productivity losses annually [10].”
InfluentialRuiz‐Medrano, J., Puertas, M., Hinojosa-Gonzalez, M., Moreno-Alboran, C., & Ruiz‐Moreno, J. M. (2026) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2026.3800 · Cited by 1
Self-citationWillmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
Encuesta sobre la situación actual de la terapia intravítrea en España
Garay‐Aramburu, G., Zarranz‐Ventura, J., Escobar-Barranco, J. J., García‐Layana, A., Neila, E. R., Donate-López, J., Cervera-Taulet, E., Calvo-Perez, P., Gómez-Resa, M., Lopez-Galvez, M. I., et al. (2026) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2026.502532
Self-citation
Metadata
- Authors
- Abraldes, M. J., Calvo, P., Gámez Lechuga, M., Merino, M., Martín Lorenzo, T., Maravilla-Herrera, P., Gil Jiménez, B., & Ruiz-Moreno, J. M.
- Affiliations
- Complejo Hospitalario Universitario de Santiago (ES)
- Hospital Universitario Miguel Servet (ES)
- Weber (ES)
- Corresponding author
- Merino, María
- Venue
- Ophthalmology and Therapy
- Published
- 2024-05-21
- Volume
- 13
- Issue
- 7
- Pages
- 1925-1935
- ISSN
- 2193-6528 (ISSN-L)
- 2193-8245
- PMC
- PMC11178696
- OpenAlex
- W4398156621
- Cited by
- 6
- References
- 21
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 1
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Ophthalmology and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Roche Farma S.A.
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, economic burden of disease, health care costs, labor productivity loss, quality of life, vision loss, Spain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
